Information Provided By: 
Fly News Breaks for July 23, 2019
MRNS
Jul 23, 2019 | 11:27 EDT
Mizuho analyst Difei Yang cut her price target on Marinus Pharmaceuticals to $1.70 from $5.00 after ganaxolone did not achieve separation from placebo in the company's postpartum depression study. Given the oral ganaxolone data presented, Yang said she does not believe the company will pursue a Major Depressive Disorder indication for the drug, adding that management said it plans to potentially move forward with an IV-only formulation for postpartum depression. She keeps a Neutral rating on Marinus shares.
News For MRNS From the Last 2 Days
There are no results for your query MRNS
